61199-34-6

Basic information

• Product Name: 3H-Pyrazol-3-one, 5-cyclohexyl-2,4-dihydro-2-methyl-
• CAS NO: 61199-34-6
• Molecular Formula: C10H16N2O
• Molecular Weight: 180.25
• Mol File: 61199-34-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3H-Pyrazol-3-one, 5-cyclohexyl-2,4-dihydro-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-Pyrazol-3-one, 5-cyclohexyl-2,4-dihydro-2-methyl-(61199-34-6)
• EPA Substance Registry System: 3H-Pyrazol-3-one, 5-cyclohexyl-2,4-dihydro-2-methyl-(61199-34-6)

Safety Data

• Hazardous Substances Data: 61199-34-6(Hazardous Substances Data)

Upstream product

• 26845-41-0 ethyl 3-(3-oxocyclohexyl)propanoate 
• 60-34-4 methylhydrazine 
• 15971-92-3 ethyl 3-cyclohexyl-3-oxopropanoate 

Downstream Products

• 132026-62-1 (5-Cyclohexyl-2-methyl-4-nitro-2H-pyrazol-3-yl)-methyl-amine 
• 132026-58-5 5-chloro-3-cyclohexyl-4-nitro-1-methylpyrazole 
• 132026-71-2 5-Cyclohexyl-2,N³-dimethyl-2H-pyrazole-3,4-diamine 
• 61199-35-7 5-Chloro-3-cyclohexyl-1-methylpyrazole 

Relevant articles and documents

Novel Antagonists of Platelet-Activating Factor. 2. Synthesis and Structure-Activity Relationships of Potent and Long-Acting Heterofused Benzodiazepine and Diazepine Derivatives of 2-Methyl-1-phenylimidazopyridine

The optimization of in vitro activty and oral potency and duration of action in vivo is described for three novel structural types of platelet-activating factor (PAF) antagonist: benzodiazepines 5-12 onto which a variety of other heterocyclic rings were fused, pyridodiazepinones 13-26, and pyrazolodiazepinones 27-46.Compounds 5-12 were prepared by elaboration of the benzodiazepine-2-thiones 47 and 48, and 13-46 were prepared by cyclocondensation reactions of a variety of 2,3-diaminopyridine and 4,5-diaminopyrazole derivatives with ethyl 4'-(2-methylimidazopyrid-1-yl)benzoylacetate (53).The presence of imine-enamine tautomerism was observed in certain diazepine derivatives and is discussed.Structure-activity relationships were evaluated where PAF antagonist activity was measured in vitro by determining the concentration of compound (IC50) required to inhibit PAF-induced aggregation of rabbit washed platelets and in vivo by determining the oral dose (ED50) which protected mice from a lethal injection of PAF.In addition, the duration of action in conscious dogs was measured by determining the oral dose of selected compounds required to inhibit completely PAF-induced whole blood aggregation ex vivo.The most potent compound was 1,6,7,8-tetrahydro-1,8-dimethyl-5-pyrid-1-yl)phenyl>-7-oxo-3-(3-pyridyl)pyrazolodiazepine (43, UK-91,473) (IC50=2.4 nM, ED50=0.01 mg/kg po), which was found to be significantly more potent in vivo (murine lethality) than the dihydropyridine PAF antagonist 4-(2-chlorophenyl)-1,4-dihydro-3-(ethoxycarbonyl)-6-methyl-4-pyrid-1-yl)phenyl>-5-pyridine (4, UK-74,505) (ED50=0.26 mg/kg po).Compound 43 also possessed a longer duration of action than compound 4 in the conscious dog at one-fourth of the dose.The crystal structure of compound 43, established by X-ray diffraction, is reported.